1. Home
  2. CAST vs VTVT Comparison

CAST vs VTVT Comparison

Compare CAST & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FreeCast Inc. Class A Common Stock

CAST

FreeCast Inc. Class A Common Stock

N/A

Current Price

$1.25

Market Cap

162.3M

Sector

Technology

ML Signal

N/A

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$35.80

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAST
VTVT
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.3M
148.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
CAST
VTVT
Price
$1.25
$35.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$6.00
$53.00
AVG Volume (30 Days)
448.6K
94.1K
Earning Date
06-26-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$14.03
52 Week High
$12.20
$44.00

Technical Indicators

Market Signals
Indicator
CAST
VTVT
Relative Strength Index (RSI) 33.75 58.92
Support Level $1.10 $33.57
Resistance Level $1.99 $35.06
Average True Range (ATR) 0.23 1.84
MACD -0.06 0.34
Stochastic Oscillator 8.23 88.07

Price Performance

Historical Comparison
CAST
VTVT

About CAST FreeCast Inc. Class A Common Stock

FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and streaming services.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: